Search Results

You are looking at 11 - 20 of 190 items for :

  • "Renal cell carcinoma" x
  • Refine by Access: All x
Clear All
Full access

Management of Renal Cell Carcinoma

Presented by: Michael Serzan

Adjuvant Therapy for Clear Cell Renal Cell Carcinoma Vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) have been extensively studied in the adjuvant setting for patients with renal cell carcinoma (RCC). Although

Full access

Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy

Carlotta Palumbo, Francesco A. Mistretta, Sophie Knipper, Angela Pecoraro, Zhe Tian, Shahrokh F. Shariat, Fred Saad, Claudio Simeone, Alberto Briganti, Alessandro Antonelli, and Pierre I. Karakiewicz

-up have a higher probability of remaining disease-free. 1 However, the magnitude of improved survival is difficult to estimate. Two studies 2 , 3 address cancer-specific CS in patients with nonmetastatic renal cell carcinoma (nmRCC): one is a population

Full access

Biallelic TSC2 Mutations in a Patient With Chromophobe Renal Cell Carcinoma Showing Extraordinary Response to Temsirolimus

Pablo Maroto, Georgia Anguera, Juan Maria Roldan-Romero, Maria Apellániz-Ruiz, Ferran Algaba, Jacqueline Boonman, Mark Nellist, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, and Cristina Rodríguez-Antona

Chromophobe renal cell carcinoma (chRCC) is the third most frequent kidney cancer histologic subtype, accounting for approximately 5% of all RCC cases. At diagnosis, chRCC is generally confined to the kidney but can metastasize. At advanced stages

Full access

Exceptional Response to Temsirolimus in a Metastatic Clear Cell Renal Cell Carcinoma With an Early Novel MTOR-Activating Mutation

Juan Francisco Rodríguez-Moreno, María Apellaniz-Ruiz, Juan María Roldan-Romero, Ignacio Durán, Luis Beltrán, Cristina Montero-Conde, Alberto Cascón, Mercedes Robledo, Jesus García-Donas, and Cristina Rodríguez-Antona

Treatment of advanced renal cell carcinoma (RCC) has changed drastically in the past decade. The mTORC1 inhibitors, everolimus and temsirolimus (also known as rapalogs ), have been shown to be key drugs for use in first-line treatment 1 and

Full access

Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and Thyroid Cancer Treated With VEGFR TKIs

Vivek Narayan, Tao Liu, Yunjie Song, Joshua Mitchell, JoRean Sicks, Ilana Gareen, Lova Sun, Srinivas Denduluri, Ciaran Fisher, Jesse Manikowski, Mark Wojtowicz, Joseph Vadakara, Naomi Haas, Kenneth B. Margulies, and Bonnie Ky

systemic treatment approach for patients with advanced renal cell carcinoma (RCC) and thyroid cancer (TC), which represent the most common prescription indications. Indeed, prolonged VEGFR signaling inhibition with VEGFR TKIs is commonly used for several

Full access

Optimal Surveillance Strategies After Surgery for Renal Cell Carcinoma

Mark D. Tyson and Sam S. Chang

The incidence of renal cell carcinoma (RCC) has been steadily increasing for decades. 1 The mainstay of treatment for clinically localized disease is radical nephrectomy and, when technically feasible, partial nephrectomy. Yet, up to 20% to 30

Full access

Spine Radiosurgery in the Management of Renal Cell Carcinoma Metastases

Neil K. Taunk, Daniel E. Spratt, Mark Bilsky, and Yoshiya Yamada

Identify those patients with metastatic RCC who may benefit the most from SRS treatment Renal Cell Carcinoma and the Case for Local Therapy for Metastatic Disease Renal cell carcinoma (RCC) is the seventh most common malignancy in the United

Full access

Incorporating New Systemic Therapies in Kidney Cancer Treatment

Eric Jonasch

Over the past decade, a number of new therapies have been approved for the treatment of renal cell carcinoma (RCC; Figure 1 ). Most treatments are driven by clear cell histology, which represents 70% to 75% of all RCCs. Eric Jonasch, MD

Full access

Integrating Immunotherapy Into the Management of Renal Cell Carcinoma

Matthew Zibelman and Elizabeth R. Plimack

. Combination Phase III Trials Using Immune Checkpoint Blockade in First-Line Metastatic Renal Cell Carcinoma referred after surgery by urologists to medical oncologists, removing the potential impact of systemic therapy on surgical timing and outcome

Full access

NCCN Guidelines Updates: Management of Metastatic Kidney Cancer

Eric Jonasch

replace current options in the upfront metastatic setting for clear cell renal cell carcinoma (ccRCC), based on recently reported pivotal trials. Some of these new regimens are not yet incorporated into the NCCN Guidelines, but are expected to be soon